Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05177549
Other study ID # 19-AOI-01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 8, 2022
Est. completion date February 15, 2025

Study information

Verified date June 2023
Source Centre Hospitalier Universitaire de Nice
Contact Christian ROUX
Phone 04 92 03 92 20
Email roux.c2@chu-nice.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Women's participation in sports at all levels has been increasing in recent decades. Many individual and team sports are at risk of anterior cruciate ligament (ACL) injury. This injury leads to a permanent or long-lasting interruption of sports practice and to significant medical and economic expenses. Women are recognized as being more at risk of anterior cruciate ligament injury with a risk 6 times higher than men. Hyperlaxity is a risk factor for anterior cruciate ligament injury, but the pathophysiological bases are little studied. Hormonal impregnation and certain periods of the menstrual cycle (ovulatory phase) are risk factors for anterior cruciate ligament injury. It therefore seems interesting to investigators to study the influence of hormonal impregnation on ligament laxity. To date no study has investigated such a relationship.


Recruitment information / eligibility

Status Recruiting
Enrollment 90
Est. completion date February 15, 2025
Est. primary completion date June 8, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - Woman between 18 and 40 years old - No history of surgery of the 2 lower limbs - No change in contraceptive method in the last 6 months - Signature of the informed consent - Affiliation to the social security system - To be at Day 14 of her menstrual cycle (+/-1 day) (the first day of the cycle (Day1) being considered as the first day of the menstrual period), except for those on micro-progestative contraception not regulated By inclusion group: - For women without hormonal contraception: No method of contraception Or a copper intrauterine device Regular cycles of 26 to 33 days - For women on estrogen-progestin contraception: Correct use of the estrogen-progestin pill according to the MA Or wearing a vaginal ring according to the MA protocol Or wearing a contraceptive skin patch according to the MA protocol Regular cycles of 26 to 33 days - For women on micro-progestin contraception : Continuous use of the micro-progestogen pill Or wearing a subcutaneous hormonal implant, Exception: women on micro-progestin contraception who are not regulated: - They may have an irregular cycle or no cycle to be included - They can be included on any day if they have no cycle Exclusion Criteria: - Pregnancy or breastfeeding in progress - Hormonal intrauterine device or injectable contraception - Menopause (defined as no menstruation for one year) - Surgery: tubal ligation, oophorectomy, adnexectomy, hysterectomy - History of microcrystalline or infectious pathology localized to the knee - History of systemic or localized inflammatory joint disease of the knee - History of fracture, severe sprain or dislocation of the knee joint - History of osteoarticular or congenital diseases that may lead to laxity (Marfan syndrome, trisomy 21, Ehlers-Danlos syndrome...) - Sign of hyperlaxity evaluated by a Beighton score higher than 4 (see appendix) - BMI > 25 - Daily alcohol consumption above the thresholds recommended by Public Health in France (more than 2 glasses per day) - Woman unable to understand the protocol - Intense or unusual physical exercise during the last 72 hours (e.g.: marathon, triathlon, competitive cycling race...) - Woman under guardianship, curatorship or deprived of liberty

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Bilateral knee examination with Lachmeter®
Bilateral knee examination with Lachmeter®. Examination repeated 3 times on each knee

Locations

Country Name City State
France CHU de Nice Nice

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary anterior tibial translation of the knee The anterior tibial translation of the knee will be considered as representative of the anterior laxity of the knee of women under hormonal contraception via the Lachman test at 30° measured with a digital arthrometer type Lachmeter® (bilateral examination repeated 3 times on each knee).The degree of laxity will be evaluated thanks to the international classification IKDC:
Grade A 0 to 2 mm = normal
Grade B 3 to 5 mm = almost normal
Grade C 6 to 10 mm = abnormal
Grade D > 10 mm = severely abnormal
Day1 (inclusion visit)
See also
  Status Clinical Trial Phase
Completed NCT03747198 - Methylsulfonylmethane on Knee Laxity N/A
Completed NCT05763108 - Clinical Significance and Coexistence of Polymorphisms of Individual Collagen-coding Genes